{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-24-000018","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2024-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.936352+00:00","generated_at":"2026-05-31T16:18:39.086390+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NovoCure Q2 revenue $150M (+19% YoY), net loss $33.4M, METIS trial positive","bullets":["Net revenues $150.4M, up 19% YoY; U.S. contributed $95.7M, Germany $15.1M, France $14.3M.","Net loss $33.4M ($0.31 per share); adjusted EBITDA $1.1M; cash and investments $951.2M.","Phase 3 METIS trial in brain metastases from NSCLC met primary endpoint; presented at ASCO 2024.","Active patients 3,963 as of June 30, 2024; prescriptions 1,634, up 5% YoY.","Gross margin 77%; research & development expenses $55.0M; sales & marketing $56.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-24-000018","json":"https://secwatch.observer/filing/0001645113-24-000018.json","markdown":"https://secwatch.observer/filing/0001645113-24-000018.md","text":"https://secwatch.observer/filing/0001645113-24-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000018/0001645113-24-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000018/nvcr-20240725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T16:18:39.086390+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}